ACET

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 4

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 138,076

F6 · kind: Represents a gift of Common Stock made on December 23, 2021.

F8 · ownership.nature: Shares held in a revocable trust of which Dr. Jakobovits and her spouse are co-trustees.

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 3

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F6 · kind: Represents a gift of Common Stock made on December 23, 2021.

F7 · ownership.nature: Shares transferred from a grantor retained annuity trust ("GRAT") of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary. Following this transaction, this GRAT was terminated.

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 332,553

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.47 to $16.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 332,552

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.46 to $16.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

SEC source: 0000947871-21-001280 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 242,285

F2 · shares: These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering.

F4 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis.

F7 · ownership.nature: This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon ("Gordon") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-21-001281 · ownership.xml · nonDerivative · entry 3

GORDON CARL L · CIK 0001282930 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 242,285

F2 · shares: These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering.

F4 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis.

F7 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, Genesis, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, Genesis, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000905718-21-001587 · adicetbio_fm4dec82021.xml · nonDerivative · entry 1

Sinclair Andrew · CIK 0001762451 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,140,721

F1 · ownership.nature: The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on December 10, 2021. These shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP ("Abingworth GP 8"), serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP 8) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.

F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. The Reporting Person is a member of the investment committee of ABV 8. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV 8 to employees of Abingworth LLP, subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-21-001591 · adicetbio_fm4amdec82021.xml · nonDerivative · entry 1

Sinclair Andrew · CIK 0001762451 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,115,385

F1 · ownership.nature: The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on December 10, 2021. These shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP ("Abingworth GP 8"), serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP 8) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.

F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. The Reporting Person is a member of the investment committee of ABV 8. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV 8 to employees of Abingworth LLP, subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-065375 · doc4.xml · derivative · entry 1

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2031-11-16

F1 · derivative.exercise_date: These shares shall vest in thirty-six (36) equal monthly installments beginning November 17, 2021.

SEC source: 0001209191-21-060360 · doc4.xml · derivative · entry 2

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2031-10-11

F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on October 12, 2022, and the remainder of the shares shall vest in equal monthly installments for a period of 36 months thereafter, subject to continued service with the Company.

SEC source: 0001209191-21-060360 · doc4.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 12, 2022 and the second tranche vesting on October 12, 2023. The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-21-059577 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,000

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-21-059574 · doc4.xml · nonDerivative · entry 1

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-21-059571 · doc4.xml · nonDerivative · entry 1

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,983

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-21-059569 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-21-042000 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 89,836

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $10.32 to $10.86, inclusive.

F4 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-042000 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 74,841

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $10.32 to $10.86, inclusive.

F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-041630 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 215,883

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-041630 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 215,883

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-040232 · doc4.xml · derivative · entry 1

ABBOT STEWART · CIK 0001655597 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2031-06-10

F1 · derivative.exercise_date: The shares underlying this option shall vest in twelve equal monthly installments commencing on June 11, 2021.

SEC source: 0001209191-21-039073 · doc4.xml · derivative · entry 2

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,441

Underlying: Common Stock · 6,983 shares

Expires 2029-10-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."

F1 · derivative.exercise_date: 25% of the option vested on September 23, 2020, and 1/36th of the remaining unvested option vests on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Galimi remains in continuous service as of the applicable vesting date.

SEC source: 0001209191-21-039073 · doc4.xml · nonDerivative · entry 1

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-038758 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 98,818

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.60 to $12.39, inclusive.

F4 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-038758 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 82,325

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.60 to $12.39, inclusive.

F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-034631 · doc4.xml · nonDerivative · entry 4

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 217,806

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-034631 · doc4.xml · nonDerivative · entry 3

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 217,807

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-034929 · doc4.xml · nonDerivative · entry 4

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 107,800

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $13.69 to $13.79, inclusive.

F5 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-034929 · doc4.xml · nonDerivative · entry 3

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 108,533

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.69 to $13.66, inclusive.

F5 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-034929 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 89,809

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $13.69 to $13.79, inclusive.

F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-034929 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 90,421

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.69 to $13.66, inclusive.

F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-034631 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 218,706

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-034631 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 218,699

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-032740 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 221,806

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.05 to $13.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: The Reporting Person previously transferred 149,307 shares and 149,306 shares from the trust described in footnote (7) to the trusts described in footnotes (4) and (6), respectively.

F6 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-032740 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 221,807

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.97 to $13.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: The Reporting Person previously transferred 149,307 shares and 149,306 shares from the trust described in footnote (7) to the trusts described in footnotes (4) and (6), respectively.

F4 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-030874 · doc4.xml · nonDerivative · entry 4

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 116,782

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.53 to $15.04, inclusive.

F5 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-030874 · doc4.xml · nonDerivative · entry 3

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 120,452

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $13.51 to $14.48, inclusive.

F5 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-030874 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 97,293

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.53 to $15.04, inclusive.

F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-030874 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 100,351

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $13.51 to $14.48, inclusive.

F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0001209191-21-030102 · doc4.xml · derivative · entry 2

Sinclair Andrew · CIK 0001762451 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,172

Underlying: Common Stock · 8,172 shares

Expires 2031-04-29

F2 · derivative.exercise_date: These shares shall vest in thirty-six (36) equal monthly installments beginning March 2, 2021.

SEC source: 0001209191-21-030102 · doc4.xml · derivative · entry 1

Sinclair Andrew · CIK 0001762451 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-21-030101 · doc4.xml · derivative · entry 2

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,172

Underlying: Common Stock · 1,172 shares

Expires 2031-04-29

F2 · derivative.exercise_date: These shares shall vest in thirty-six (36) equal monthly installments beginning December 1, 2020.

SEC source: 0001209191-21-030101 · doc4.xml · derivative · entry 1

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-21-030098 · doc4.xml · derivative · entry 1

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-21-030100 · doc4.xml · derivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-21-030097 · doc4.xml · derivative · entry 1

DUBIN STEVE · CIK 0001265123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-21-030095 · doc4.xml · derivative · entry 1

Chodakewitz Jeffrey · CIK 0001610876 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-21-016753 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 104,777

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.76 to $12.27, inclusive.

F4 · ownership.nature: Represents 104,777 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-016753 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 125,764

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.76 to $12.27, inclusive.

F3 · ownership.nature: Represents 125,764 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-015390 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 112,261

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.61 to $13.38, inclusive.

F4 · ownership.nature: Represents 112,261 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-015390 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 134,746

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.61 to $13.38, inclusive.

F3 · ownership.nature: Represents 134,746 shares held directly by an irrevocable family trust having an independent trustee.